Netherton's syndrome

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Unknown / small molecule 1 substance
Phase II/III: 1 Phase I/II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II/III

1 trial
  • Boehringer Ingelheim International GmbH Commercial
    SPESOLIMAB
    2022-501104-10-00 11 countries 2023 n=20
    Ended

Phase I/II

1 trial
  • Daiichi Sankyo Inc. Commercial
    DS-2325A
    2022-502853-32-00 1 country 2023 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Boehringer Ingelheim International GmbH Commercial 1 Phase II/III 0
Daiichi Sankyo Inc. Commercial 1 Phase I/II 0
New trials by year
2023
2
← All indication landscapes